HYDROFLUMETHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hydroflumethiazide, and when can generic versions of Hydroflumethiazide launch?
Hydroflumethiazide is a drug marketed by Par Pharm, Watson Labs, and Usl Pharma. and is included in six NDAs.
The generic ingredient in HYDROFLUMETHIAZIDE is hydroflumethiazide; reserpine. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide; reserpine profile page.
Summary for HYDROFLUMETHIAZIDE
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 82 |
Clinical Trials: | 1 |
Patent Applications: | 4,652 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HYDROFLUMETHIAZIDE at DailyMed |
Recent Clinical Trials for HYDROFLUMETHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Pfizer |